The Cracow-based company, offering innovative technological solutions in medicine (medtech), achieved a net result in the first half of this year, similar to the level for the whole of last year. The financial results generated in the second quarter of 2021 maintain a high growth rate, because of the development of the international distribution network and the expansion of the functionality of innovative technological solutions, including CarnaLife Holo (holographic visualization to support the planning and execution of medical procedures) and CarnaLife System (digital medicine platform for remote patient monitoring and diagnosis).
In the second quarter of 2021, the company reported revenue of PLN 3,528 million and net profit of PLN 1,462 million , EBIDTA of the second quarter of 2021 was PLN 2,186 million.
In total, in the first half of 2021, MedApp generated revenues of PLN 5,472,000 and a net profit of PLN 1,838,000. The results generated in the first half of 2021 are similar to the results the Company generated for the whole of 2020 when revenues amounted to PLN 6,025,000 and a net profit to PLN 1,915,000.
– We have acquired further distributors in Poland and in the European market – in France and Luxembourg – while developing other sales channels. We consistently expand the functionality of our leading solutions, CarnaLife Holo and CarnaLife System – comments Krzysztof Mędrala, CEO of MedApp S.A.
In July this year, three-dimensional medical data visualization technology – CarnaLife Holo – made it possible for teams of Polish and Bulgarian vascular surgeons, who were 1,500 km apart at the time of the intervention, to consult on the procedure.
– This is a crucial moment that shows how our software, CarnaLife Holo, can also be used for remote treatments. We are pleased to see an increasing number of hospitals, clinics, and outpatient clinics using MedApp’s proprietary technologies on a daily basis so that we have an impact on increasing the quality of domestic and international medical services based on mixed reality solutions, big data analytics, and artificial intelligence. We are determined to support doctors and patients around the world. I believe that thanks to the IPO, which we would like to carry out in the third quarter of 2021, we will maintain the current dynamics of the development of our Company – adds Krzysztof Mędrala, the CEO of MedApp S.A
The second quarter of 2021 will see further consistent implementation of MedApp’s growth strategy, based on sales expansion while developing its product offering. The company has entered a partnership with its French distributor, FP Business SAS, under which CarnaLife Holo technology will be used in hospitals and medical facilities in France and Luxembourg. The channels for reaching out to hospital facilities and university hospitals in Poland have also been expanded by entering into a distribution agreement with Medical Idea.
MedApp has also continued to develop the products it offers. In June this year, the CarnaLife System platform was enriched with the Microsoft Teams application, thanks to which partner facilities have gained another convenient, simple and safe, in terms of medical data circulation, a tool for communication during medical consultations with patients. The use of the CarnaLife Holo app in vascular surgery and ENT oncology has also been expanded.
The company is preparing for its debut on the Main Market of the Warsaw Stock Exchange. The prospectus is currently under review by the Financial Supervision Commission.
Contact for the media :
PR and Communication Manager, MedApp S.A.
+48 534 364 532
P&L Investor Relations
+48 506 324 456
Read more See similar articles:
MedApp is the laureate of the Special Award of PARP and NCBR
During the Gala of the 24th edition of the Polish Product of the Future competition, we received a special award from the Polish Agency for Enterprise Development and the National Center for Research and Development!
East Value Research Analyst Report – update
An independent analyst report prepared by analysts at East Value Research was released today.
MedApp with record FY 2021 results, doubling revenue and profits from previous year
MedApp reported PLN 12.7 million in net sales revenue cumulatively after four quarters of 2021, 111% higher than a year earlier. EBITDA increased by 139% to PLN 6.3 million, and net profit was twice higher year-on-year, reaching PLN 3.8 million. The company also boasts high profitability.